The genomic basis of adaptation to the fitness cost of rifampicin resistance in pseudomonas aeruginosa

Proceedings of the Royal Society B: Biological Sciences

Volumn 283, Issue 1822, 2016, Pages

  Qi, Qin ^a,b   Toll Riera, Macarena ^a,c   Heilbron, Karl ^a   Preston, Gail M ^a   Maclean, R Craig ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA   (Austria)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Compensatory adaptation; Experimental evolution; General adaptation; Rifampicin resistance; Whole genome sequencing

Indexed keywords

ADAPTATION; ANTIBIOTIC RESISTANCE; BACTERIUM; ENZYME ACTIVITY; EXPERIMENTAL STUDY; FITNESS; GENE EXPRESSION; GENOMICS; MUTATION; PATHOGEN;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA;

ANTIINFECTIVE AGENT; RIFAMPICIN;

ADAPTATION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENETICS; GENOMICS; PSEUDOMONAS AERUGINOSA; REPRODUCTIVE FITNESS;

ADAPTATION, BIOLOGICAL; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENETIC FITNESS; GENOMICS; PSEUDOMONAS AERUGINOSA; RIFAMPIN;

EID: 84955558494     PISSN: 09628452     EISSN: 14712954     Source Type: Journal    
DOI: 10.1098/rspb.2015.2452     Document Type: Article

References (73)

1. Andersson DI. 2006 The biological cost of mutational antibiotic resistance: any practical conclusions? Curr. Opin. Microbiol. 9, 461–465. (doi:S1369-5274(06)00121-4)
2. MacLean RC, Hall A, Perron G, Buckling A. 2010 The population genetics of antibiotic resistance: integrating molecular mechanisms and treatment contexts. Nat. Rev. Genet. 11, 405–414. (doi:10.1038/nrg2778)
3. Andersson DI, Hughes D. 2010 Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8, 260–271. (doi:10.1038/nrmicro2319)
4. Maisnier-Patin S, Andersson DI. 2004 Adaptation to the deleterious effects of antimicrobial drug resistance mutations by compensatory evolution. Res. Microbiol. 155, 360–369. (doi:10.1016/j.resmic.2004.01.019)
5. Qi Q, Preston GM, MacLean RC. 2014 Linking system-wide impacts of RNA polymerase mutations to the fitness cost of rifampin resistance in Pseudomonas aeruginosa. mBio 5, e01562. (doi:10.1128/mBio.01562-14)
6. Nagaev I, Bjorkman J, Andersson DI, Hughes D. 2001 Biological cost and compensatory evolution in fusidic acid-resistant Staphylococcus aureus. Mol. Microbiol. 40, 433–439. (doi:10.1046/j.1365-2958.2001.02389.x)
7. Brandis G, Hughes D. 2013 Genetic characterization of compensatory evolution in strains carrying rpoB Ser531Leu, the rifampicin resistance mutation most frequently found in clinical isolates. J. Antimicrob. Chemother. 68, 2493–2497. (doi:10.1093/jac/dkt224)
8. Reynolds MG. 2000 Compensatory evolution in rifampin-resistant Escherichia coli. Genetics 156, 1471–1481.
9. Zorzet A, Pavlov MY, Nilsson AI, Ehrenberg M, Andersson DI. 2010 Error-prone initiation factor 2 mutations reduce the fitness cost of antibiotic resistance. Mol. Microbiol. 75, 1299–1313. (doi:10.1111/j.1365-2958.2010.07057.x)
10. Zhang L, Watson LT. 2009 Analysis of the fitness effect of compensatory mutations. HFSP J. 3, 47–54. (doi:10.2976/1.2990075)
11. Estes S, Phillips PC, Denver DR. 2011 Fitness recovery and compensatory evolution in natural mutant lines of C. elegans. Evolution 65, 2335–2344. (doi:10.1111/j.1558-5646.2011.01276.x)
12. Andersson DI, Levin B. 1999 The biological cost of antibiotic resistance. Curr. Opin. Microbiol. 2, 489–493. (doi:10.1016/S1369-5274(99)00005-3)
13. Schulz zur Wiesch P, Engelstädter J, Bonhoeffer S. 2010 Compensation of fitness costs and reversibility of antibiotic resistance mutations. Antimicrob. Agents Chemother. 54, 2085–2095. (doi:10.1128/AAC.01460-09)
14. Hughes D, Andersson DI. 2015 Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms. Nat. Rev. Genet. 16, 459–471. (doi:10.1038/nrg3922)
15. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-Maeda M, Galagan J, Niemann S, Gagneux S. 2012 Whole-genome sequencing of rifampicinresistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44, 106–110. (doi:10.1038/ng.1038)
16. de Vos M, Muller B, Borrell S, Black PA, van Helden PD, Warren RM, Gagneux S, Victor TC. 2013 Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob. Agents Chemother. 57, 827–832. (doi:10.1128/AAC. 01541-12)
17. Perdigão J et al. 2014 Unraveling Mycobacterium tuberculosis genomic diversity and evolution in Lisbon, Portugal, a highly drug resistant setting. BMC Genomics 15, 991. (doi:10.1186/1471-2164-15-991)
18. Poon A, Davis BH, Chao L. 2005 The coupon collector and the suppressor mutation: estimating the number of compensatory mutations by maximum likelihood. Genetics 170, 1323–1332. (doi:10.1534/genetics.104.037259)
19. Wielgoss S, Barrick JE, Tenaillon O, Cruveiller S, Chane-Woon-Ming B, Medigue C, Lenski RE, Schneider D, Andrews BJ. 2011 Mutation rate inferred from synonymous substitutions in a longterm evolution experiment with Escherichia coli. G3 (Bethesda) 1, 183–186. (doi:10.1534/g3.111.000406)
20. Barrett RD, MacLean RC, Bell G. 2006 Mutations of intermediate effect are responsible for adaptation in evolving Pseudomonas fluorescens populations. Biol. Lett. 2, 236–238. (doi:10.1098/rsbl.2006.0439)
21. Imhof M, Schlotterer C. 2001 Fitness effects of advantageous mutations in evolving Escherichia coli populations. Proc. Natl Acad. Sci. USA 98, 1113–1117. (doi:10.1073/pnas.98.3.1113)
22. Perfeito L, Fernandes L, Mota C, Gordo I. 2007 Adaptive mutations in bacteria: high rate and small effects. Science 317, 813–815. (doi:10.1126/science.1142284)
23. Stevens KE, Sebert ME. 2011 Frequent beneficial mutations during single-colony serial transfer of Streptococcus pneumoniae. PLoS Genet. 7, e1002232. (doi:10.1371/journal.pgen.1002232)
24. Rozen DE, de Visser JA, Gerrish PJ. 2002 Fitness effects of fixed beneficial mutations in microbial populations. Curr. Biol. 12, 1040–1045. (doi:10.1016/S0960-9822(02)00896-5)
25. Bell G. 2008 Selection: the mechanism of evolution, 2nd edn. Oxford, UK: Oxford University Press.
26. Brandis G, Wrande M, Liljas L, Hughes D. 2012 Fitness-compensatory mutations in rifampicinresistant RNA polymerase. Mol. Microbiol. 85, 142–151. (doi:10.1111/j.1365-2958.2012.08099.x)
27. Szamecz B et al. 2014 The genomic landscape of compensatory evolution. PLoS Biol. 12, e1001935. (doi:10.1371/journal.pbio.1001935)
28. Nilsson AI, Zorzet A, Kanth A, Dahlstrom S, Berg OG, Andersson DI. 2006 Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl Acad. Sci. USA 103, 6976–6981. (doi:10.1073/pnas.0602171103)
29. Maisnier-Patin S, Berg OG, Liljas L, Andersson DI. 2002 Compensatory adaptation to the deleterious effect of antibiotic resistance in Salmonella typhimurium. Mol. Microbiol. 46, 355–366. (doi:10.1046/j.1365-2958.2002.03173.x)
30. Kugelberg E, Lofmark S, Wretlind B, Andersson DI. 2005 Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa. J. Antimicrob. Chemother. 55, 22–30. (doi:10.1093/jac/dkh505)
31. Björkman J, Nagaev I, Berg OG, Hughes D, Andersson DI. 2000 Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287, 1479–1482. (doi:10.1126/science.287.5457.1479)
32. Schrag SJ, Perrot V. 1996 Reducing antibiotic resistance. Nature 381, 120–121. (doi:10.1038/381120b0)
33. Stern DL. 2013 The genetic causes of convergent evolution. Nat. Rev. Genet. 14, 751–764. (doi:10.1038/nrg3483)
34. Tenaillon O, Rodriguez-Verdugo A, Gaut RL, McDonald P, Bennett AF, Long AD, Gaut BS. 2012 The molecular diversity of adaptive convergence. Science 335, 457–461. (doi:10.1126/science.1212986)
35. Lieberman TD et al. 2011 Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat. Genet. 43, 1275–1280. (doi:10.1038/ng.997)
36. Farhat MR et al. 2013 Genomic analysis identifies targets of convergent positive selection in drugresistant Mycobacterium tuberculosis. Nat. Genet. 45, 1183–1189. (doi:10.1038/ng.2747)
37. Schrag SJ, Perrot V, Levin BR. 1997 Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. R. Soc. Lond. B 264, 1287–1291. (doi:10.1098/rspb.1997.0178)
38. Hall AR, Griffiths VF, MacLean RC, Colegrave N. 2010 Mutational neighbourhood and mutation supply rate constrain adaptation in Pseudomonas aeruginosa. Proc. R. Soc. B 277, 643–650. (doi:10.1098/rspb.2009.1630)
39. Schuster M, Lostroh CP, Ogi T, Greenberg EP. 2003 Identification, timing, and signal specificity of Pseudomonas aeruginosa quorumcontrolled genes: a transcriptome analysis. J. Bacteriol. 185, 2066–2079. (doi:10.1128/JB.185.7.2066-2079.2003)
40. Schuster M, Urbanowski ML, Greenberg EP. 2004 Promoter specificity in Pseudomonas aeruginosa quorum sensing revealed by DNA binding of purified LasR. Proc. Natl Acad. Sci. USA 101, 15 833–15 839. (doi:10.1073/pnas.0407229101)
41. Luján AM, Moyano AJ, Segura I, Argaraña CE, Smania AM. 2007 Quorum-sensing-deficient (lasR) mutants emerge at high frequency from a Pseudomonas aeruginosa mutS strain. Microbiology 153, 225–237. (doi:10.1099/mic.0.29021-0)
42. Sandoz KM, Mitzimberg SM, Schuster M. 2007 Social cheating in Pseudomonas aeruginosa quorum sensing. Proc. Natl Acad. Sci. USA 104, 15 876–15 881. (doi:10.1073/pnas.0705653104)
43. Heurlier K, Denervaud V, Haenni M, Guy L, Krishnapillai V, Haas D. 2005 Quorum-sensingnegative (lasR) mutants of Pseudomonas aeruginosa avoid cell lysis and death. J. Bacteriol. 187, 4875–4883. (doi:10.1128/JB.187.14.4875-4883.2005)
44. Jansen G, Crummenerl LL, Gilbert F, Mohr T, Pfefferkorn R, Thänert R, Rosenstiel P, Schulenburg H. 2015 Evolutionary transition from pathogenicity to commensalism: global regulator mutations mediate fitness gains through virulence attenuation. Mol. Biol. Evol. 32, 2883–2896. (doi:10.1093/molbev/msv160)
45. Smith EE et al. 2006 Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103, 8487–8492. (doi:10.1073/pnas.0602138103)
46. D’Argenio DA et al. 2007 Growth phenotypes of Pseudomonas aeruginosa lasR mutants adapted to the airways of cystic fibrosis patients. Mol. Microbiol. 64, 512–533. (doi:10.1111/j.1365-2958.2007.05678.x)
47. Albus AM, Pesci EC, Runyen-Janecky LJ, West SE, Iglewski BH. 1997 Vfr controls quorum sensing in Pseudomonas aeruginosa. J. Bacteriol. 179, 3928–3935.
48. Kiratisin P, Tucker KD, Passador L. 2002 LasR, a transcriptional activator of Pseudomonas aeruginosa virulence genes, functions as a multimer. J. Bacteriol. 184, 4912–4919. (doi:10.1128/JB.184.17.4912-4919.2002)
49. Reimmann C, Beyeler M, Latifi A, Winteler H, Foglino M, Lazdunski A, Haas D. 1997 The global activator GacA of Pseudomonas aeruginosa PAO positively controls the production of the autoinducer N-butyryl-homoserine lactone and the formation of the virulence factors pyocyanin, cyanide, and lipase. Mol. Microbiol. 24, 309–319. (doi:10.1046/j.1365-2958.1997.3291701.x)
50. Rutherford ST, Bassler BL. 2012 Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb. Perspect. Med. 2, a012427. (doi:10.1101/cshperspect.a012427)
51. Brencic A, Lory S. 2009 Determination of the regulon and identification of novel mRNA targets of Pseudomonas aeruginosa RsmA. Mol. Microbiol. 72, 612–632. (doi:10.1111/j.1365-2958.2009.06670.x)
52. Davis BH, Poon AF, Whitlock MC. 2009 Compensatory mutations are repeatable and clustered within proteins. Proc. R. Soc. B 276, 1823–1827. (doi:10.1098/rspb.2008.1846)
53. Weinreich DM, Watson RA, Chao L. 2005 Perspective: sign epistasis and genetic constraint on evolutionary trajectories. Evolution 59, 1165–1174. (doi:10.1111/j.0014-3820.2005.tb01769.x)
54. Heilbron K. 2015 The genomics of adaptation to mutational degradation in hypermutator Pseudomonas aeruginosa. DPhil thesis, University of Oxford, Oxford, UK.
55. zur Wiesch PA, Kouyos R, Engelstädter J, Regoes RR, Bonhoeffer S. 2011 Population biological principles of drug-resistance evolution in infectious diseases. Lancet Infect. Dis. 11, 236–247. (doi:10.1016/S1473-3099(10)70264-4)
56. Levin BR, Perrot V, Walker N. 2000 Compensatory mutations, antibiotic resistance and the population genetics of adaptive evolution in bacteria. Genetics 154, 985–997.
57. MacLean RC, Vogwill T. 2014 Limits to compensatory adaptation and the persistence of antibiotic resistance in pathogenic bacteria. Evol. Med. Public Health 2015, 4–12. (doi:10.1093/emph/eou032)
58. Toprak E, Veres A, Michel J-B, Chait R, Hartl DL, Kishony R. 2012 Evolutionary paths to antibiotic resistance under dynamically sustained drug selection. Nat. Genet. 44, 101–105. (doi:10.1038/ng.1034)
59. Mwangi MM et al. 2007 Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc. Natl Acad. Sci. USA 104, 9451–9456. (doi:10.1073/pnas.0609839104)
60. Buckling A, Rainey PB. 2002 The role of parasites in sympatric and allopatric host diversification. Nature 420, 496–499. (doi:10.1038/nature01164)
61. Suzuki K, Meek B, Doi Y, Muramatsu M, Chiba T, Honjo T, Fagarasan S. 2004 Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc. Natl Acad. Sci. USA 101, 1981–1986. (doi:10.1073/pnas.0307317101)
62. Lieberman TD, Flett KB, Yelin I, Martin TR, McAdam AJ, Priebe GP, Kishony R. 2014 Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat. Genet. 46, 82–87. (doi:10.1038/ng.2848)
63. Young BC et al. 2012 Evolutionary dynamics of Staphylococcus aureus during progression from carriage to disease. Proc. Natl Acad. Sci. USA 109, 4550–4555. (doi:10.1073/pnas.1113219109)
64. Sassetti CM, Rubin EJ. 2003 Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad. Sci. USA 100, 12 989–12 994. (doi:10.1073/pnas.2134250100)
65. Casali N et al. 2012 Microevolution of extensively drug-resistant tuberculosis in Russia. Genome Res. 22, 735–745. (doi:10.1101/gr.128678.111)
66. Billal DS, Feng J, Leprohon P, Legare D, Ouellette M. 2011 Whole genome analysis of linezolid resistance in Streptococcus pneumoniae reveals resistance and compensatory mutations. BMC Genomics 12, 512. (doi:10.1186/1471-2164-12-512)
67. Niemann S et al. 2009 Genomic diversity among drug sensitive and multidrug resistant isolates of Mycobacterium tuberculosis with identical DNA fingerprints. PLoS ONE 4, e7407. (doi:10.1371/journal.pone.0007407)
68. Löfmark S, Jernberg C, Billström H, Andersson DI, Edlund C. 2008 Restored fitness leads to long-term persistence of resistant bacteroides strains in the human intestine. Anaerobe 14, 157–160. (doi:10.1016/j.anaerobe.2008.02.003)
69. Karami N, Hannoun C, Adlerberth I, Wold AE. 2008 Colonization dynamics of ampicillin-resistant Escherichia coli in the infantile colonic microbiota. J. Antimicrob. Chemother. 62, 703–708. (doi:10.1093/jac/dkn263)
70. Sjölund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. 2003 Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 139, 483–487. (doi:10.7326/0003-4819-139-6-200309160-00011)
71. MacLean RC, Perron GG, Gardner A. 2010 Diminishing returns from beneficial mutations and pervasive epistasis shape the fitness landscape for rifampicin resistance in Pseudomonas aeruginosa. Genetics 186, 1345–1354. (doi:10.1534/genetics.110.123083)
72. Heilbron K, Toll-Riera M, Kojadinovic M, Maclean RC. 2014 Fitness is strongly influenced by rare mutations of large effect in a microbial mutation accumulation experiment. Genetics 197, 981–990. (doi:10.1534/genetics.114.163147)
73. Millan AS, Peña-Miller R, Toll-Riera M, Halbert ZV, McLean AR, Cooper BS, MacLean RC. 2014 Positive selection and compensatory adaptation interact to stabilize non-transmissible plasmids. Nat. Commun. 5, 5208. (doi:10.1038/ncomms6208)